-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of the China Drug Clinical Trial Registration and Information Publicity Platform shows that Merck & Co.
First-line therapy for advanced renal cell carcinoma (ccRCC) and adjuvant therapy for first-line renal cell carcinoma (RCC) is the first hypoxia-inducible factor (HIF-2α) inhibitor (HIF-2α) approved by the US FDA
Screenshot source: Drug Clinical Trial Registration and Information Publicity Platform
Belzutifan is an investigational, novel, potent, and selective oral HIF-2α inhibitor currently being evaluated in multiple clinical studies for the treatment of patients with VHL-related renal cell carcinoma, advanced renal cell carcinoma, and advanced solid tumors
Belzutifan is an investigational, novel, potent, selective oral HIF-2α inhibitor
According to the China Drug Clinical Trial Registration and Information Publicity Platform, Merck has recently launched two Phase 3 clinical trials in China
First-line treatment of subjects with advanced renal cell carcinoma The principal investigator of this study is Dr.
Subjects with clear cell renal cell carcinoma who received nephrectomy as postoperative adjuvant therapy The main investigator of this study is Dr.
Thirty patients (49%) achieved partial responses, and another 30 patients (49%) had stable disease
It is hoped that Merck's new anti-tumor drug belzutifan will progress smoothly in clinical research and bring new treatment options and clinical benefits to more cancer patients as soon as possible
References:
References:[1] Official website of China Drug Clinical Trials Registration and Information Publicity Platform.
[2] FDA approves belzutifan for cancers associated with von Hippel-Lindau disease.
[3] Jonasch et al.
, (2021).
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease.
NEJM, DOI: 10.
1056/NEJMoa2103425
